Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Inhibition of angiopoietin-like 3 (ANGPTL-3) with SHR-1918 leads to further low-density lipoprotein cholesterol (LDL-C) reductions in patients at increased risk of atherosclerotic cardiovascular disease (ASCVD), a phase II study has shown.

Temocillin a good alternative to carbapenems for bacteraemia

The use of temocillin demonstrates comparable efficacy and safety to carbapenems for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (3GCR-E), primarily from urinary sources, reports a study.

5-day antibiotic use viable in CAP patients with clinical stability

Antibiotic treatment may be done for 5 days, as opposed to at least 7 days, in hospitalized patients with community-acquired pneumonia (CAP) who had achieved clinical stability by day 3 to 5, suggests a study presented at ESCMID Global 2025.

16 May 2025

Updated EPIC-HR data bolster nirmatrelvir/ritonavir role against COVID-19

Updated data from the EPIC-HR* trial show reduced duration of COVID-19 symptoms and utilization of healthcare resources with nirmatrelvir/ritonavir (NMV/r) in high-risk, unvaccinated, nonhospitalized, symptomatic adults with COVID-19.

16 May 2025

Linaclotide improves bowel symptoms in children with functional constipation

Treatment with linaclotide led to significantly improved symptoms of incomplete bowel evacuation and straining in paediatric patients aged 6–17 years with functional constipation, according to a phase III study presented at DDW 2025.

Starting DOACs sooner after stroke may be best for AF patients

15 May 2025 bởi

For secondary stroke prevention in patients with atrial fibrillation (AF), the optimal timing of initiating a direct oral anticoagulant (DOAC) remains elusive, although evidence from a phase II study suggests that earlier initiation is better than later times within the first 2 weeks after stroke onset.

Tirzepatide eases MetS, cardiometabolic abnormalities in T2D

Individuals with type 2 diabetes (T2D) may benefit from using tirzepatide, which has been shown in a recent study to improve cardiometabolic abnormalities and resolve metabolic syndrome (MetS).

CAR T-cell therapy improves survival in non-Hodgkin lymphoma

Treatment with chimeric antigen receptor T-cell therapies (CAR-TCT) results in significant improvements in overall (OS) and progression-free survival (PFS) among patients with refractory non-Hodgkin lymphoma (NHL) but shows no substantial effect on event-free survival (EFS), reports a study.